PremiumCompany AnnouncementsPliant Therapeutics Adopts Stockholder Rights Agreement Pliant Therapeutics adopts limited duration stockholder rights agreement Biotech Alert: Searches spiking for these stocks today PremiumThe FlyPliant Therapeutics price target lowered to $1.50 from $4 at Citi Cautious Hold Rating on Pliant Therapeutics Amid Uncertainty Over Bexotegrast Trial and Financial Outlook Pliant Therapeutics reinstated with a Neutral at Cantor Fitzgerald PremiumThe FlyPliant Therapeutics downgraded at Stifel after bexotegrast study discontinued Pliant Therapeutics downgraded to Hold from Buy at Stifel Leerink downgrades Pliant Therapeutics after trial discontinuation 
